000			03593nam a22003615i 4500
001			234444
003			ES-VaUE
005			20221220020603.0
007			cr nn 008mamaa
008			100715s2010 xxu| s |||| 0|eng d
020			_a9781607618034
024	7		_a10.1007/978-1-60761-803-4 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_aAnticoagulants, Antiplatelets, and Thrombolytics _cedited by Shaker A. Mousa.
250			_a2nd edition 2010
264		1	_aTotowa, NJ _bHumana Press _c2010
300			_a1 recurso en línea (XII, 316 páginas) _b
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Biology _x1940-6029 _v663
505	0		_aIn Vitro Methods of Evaluating Antithrombotics and Thrombolytics -- In Vivo Models for the Evaluation of Antithrombotics and Thrombolytics -- Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond -- Laboratory Methods and Management of Patients with Heparin-Induced Thrombocytopenia -- Novel Anticoagulant Therapy: Principle and Practice -- Oral Direct Factor Xa Inhibitors, with Special Emphasis on Rivaroxaban -- Antiplatelet Therapies: Drug Interactions in the Management of Vascular Disorders -- Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist -- Antithrombotic Effects of Naturally Derived Products on Coagulation and Platelet Function -- Assessment of Anti-Metastatic Effects of Anticoagulant and Antiplatelet Agents Using Animal Models of Experimental Lung Metastasis -- Adhesion Molecules: Potential Therapeutic and Diagnostic Implications -- Pharmacogenomics in Thrombosis -- Diagnosis and Management of Sickle Cell Disorders.
520			_aDuring the past decade, remarkable progress has been made in the development of newer drugs to prevent and treat thromboembolic disorders, such as oral direct anti-Xa and anti-IIa antagonists, as well as oral antiplatelet ADP antagonists with rapid onset and offset. In addition, there has been concentrated effort aimed at identifying novel uses of traditional antithrombotic drugs, such as aspirin, heparin, and oral anticoagulants, as well as combinations of agents, such as more than one antiplatelet, antiplatelet with anticoagulant, antiplatelet with or without thrombolytic. Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition provides updates on various strategies in thrombosis, experimental models, and clinical and recent advances in the discovery and development of novel antithrombotics. As a volume in the highly successful Methods in Molecular Biology™ series, this collection provides the kind of detailed description and implementation advice that is crucial for getting optimal results. Easy to use and up to date, Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition is an ideal guide for researchers aiming for the future of this vital field, focusing on the prevention of thromboembolic disorders and the protection of the vascular endothelium.
700	1		_aMousa, Shaker A _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9781607618027
776	0	8	_iPrinted edition: _z9781607618041
776	0	8	_iPrinted edition: _z9781493960972
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-1-60761-803-4 _z(usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
988			_aSpringer_Protocols_2010
999			_c234444 _d234444